cefoxitin and Bronchitis

The therapeutic efficacy of cefoxitin was studied in 15 patients with pulmonary or urinary infections, after other unsuccessful antibiotic treatment. The drug determined a total regression of clinical picture within 10 days of therapy. Our results show that brief periods of treatment are sufficient in order to obtain recovery and to avoid selection of resistant germs. Patients treated with cefoxitin did not present any intolerance. The conclusion is drawn that "Mefoxin" is useful in patients affected by infections resistant to common antibiotics.

Topics: Abscess; Adult; Aged; Bronchitis; Bronchopneumonia; Buttocks; Cefoxitin; Clinical Trials as Topic; Drug Tolerance; Female; Humans; Klebsiella; Male; Middle Aged; Pyelitis; Streptococcus

We present a rare case of tracheobronchitis caused by Mycobacterium abscessus. The patient was a 79-year-old man with a previous history of tuberculosis. For smear examinations, he repeatedly expectorated many acid-fast bacilli. Bronchoscopic examination revealed the presence of ulceration on the lower end of the trachea and extending to the right main bronchus. Mycobacterial cultures were used to grow Mycobacterium abscessus. Following an antimicrobial regimen of clarithromycin, amikacin, and cefoxitin, the patient exhibited marked improvement. After initial multidrug therapy, the patient was placed on clarithromycin for 10 months. No relapse has occurred to date.

Topics: Aged; Amikacin; Anti-Bacterial Agents; Bronchial Diseases; Bronchitis; Cefoxitin; Clarithromycin; Drug Therapy, Combination; Humans; Male; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Tracheitis; Ulcer

An investigation conducted on healthy volunteers showed that cefoxitin quickly reaches high plasma concentrations, and is almost completely excreted via the urine within 6 hours. In a series of 21 cases treated with 2 g i.v. in 100 ml of a 5% glucose solution two or three times a day, a clinical cure was achieved in 20, and marked improvement in the remaining patient.

Topics: Bacillus subtilis; Bronchitis; Bronchopneumonia; Cefoxitin; Cholangitis; Cystitis; Drug Evaluation; Drug Tolerance; Gas Gangrene; Herpes Zoster; Humans; Kinetics; Osteomyelitis; Sepsis

Topics: Acute Disease; Adult; Bronchitis; Bronchopneumonia; Cefoxitin; Female; Humans; Male; Middle Aged

On 24 patients with chronic obstructive bronchitis the Cefuroxim and Cefoxitin concentrations in the sputum were investigated during 11 days after intravenous injections. The concentrations of Cefuroxim were above the minimal concentrations necessary to block growing of bacteria. Cefoxitin showed lower concentrations. Different pharmacokinetics for both of the test substances may be responsible for the different results.

Topics: Adult; Aged; Bronchitis; Cefoxitin; Cephalosporins; Chronic Disease; Female; Humans; Male; Middle Aged; Sputum

We report the results of the study of the bronchial concentrations of several antibiotics. The experiment included 280 patients and the concentrations achieved in bronchial secretions were measured for 11 antibiotics. The samples of bronchial secretions were taken in situ by fibroscopy or through the tracheostomy cannula. The results of the study show that the rate of penetration is variable according to the different drugs; even in the same antibiotic family such as beta-lactam antibiotics the rate of penetration is variable. The bronchial levels of aminoglycosides, macrolides and tetracyclines are worthwhile, and are often superior to the MIC of the infecting organisms; the penetration is also dependant of the inflammatory conditions of the bronchi. Otherwise the sampling conditions were the best possible since samples taken by fibroscopy or by tracheostomy are not contaminated by saliva which is a factor of dilutional error. The methodology used in this study is an approach of pharmacokinetics of antibiotics in respiratory tract.

Topics: Adult; Aged; Amikacin; Amoxicillin; Anti-Bacterial Agents; Bronchi; Bronchitis; Cefoxitin; Female; Humans; Kinetics; Male; Middle Aged; Oleandomycin